De novo myocardial regeneration: Advances and pitfalls

Khawaja Husnain Haider, Stephanie Buccini, Rafeeq P.H. Ahmed, Muhammad Ashraf

Research output: Contribution to journalReview article

Abstract

The capability of adult tissue-derived stem cells for cardiogenesis has been extensively studied in experimental animals and clinical studies for treatment of postischemic cardiomyopathy. The less-than-anticipated improvement in the heart function in most clinical studies with skeletal myoblasts and bone marrow cells has warranted a search for alternative sources of stem cells. Despite their multilineage differentiation potential, ethical issues, teratogenicity, and tissue rejection are main obstacles in developing clinically feasible methods for embryonic stem cell transplantation into patients. A decade-long research on embryonic stem cells has paved the way for discovery of alternative approaches for generating pluripotent stem cells. Genetic manipulation of somatic cells for pluripotency genes reprograms the cells to pluripotent status. Efforts are currently focused to make reprogramming protocols safer for clinical applications of the reprogrammed cells. We summarize the advancements and complicating features of stem cell therapy and discuss the decade-and-a-half-long efforts made by stem cell researchers for moving the field from bench to the bedside as an adjunct therapy or as an alternative to the contemporary therapeutic modalities for routine clinical application. The review also provides a special focus on the advancements made in the field of somatic cell reprogramming.

Original languageEnglish (US)
Pages (from-to)1867-1877
Number of pages11
JournalAntioxidants and Redox Signaling
Volume13
Issue number12
DOIs
StatePublished - Dec 15 2010
Externally publishedYes

Fingerprint

Stem cells
Regeneration
Stem Cells
Skeletal Myoblasts
Stem Cell Research
Pluripotent Stem Cells
Stem Cell Transplantation
Embryonic Stem Cells
Clinical Protocols
Cell- and Tissue-Based Therapy
Cardiomyopathies
Ethics
Bone Marrow Cells
Tissue
Therapeutics
Research Personnel
Bone
Animals
Genes
Cells

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology

Cite this

De novo myocardial regeneration : Advances and pitfalls. / Haider, Khawaja Husnain; Buccini, Stephanie; Ahmed, Rafeeq P.H.; Ashraf, Muhammad.

In: Antioxidants and Redox Signaling, Vol. 13, No. 12, 15.12.2010, p. 1867-1877.

Research output: Contribution to journalReview article

Haider, Khawaja Husnain ; Buccini, Stephanie ; Ahmed, Rafeeq P.H. ; Ashraf, Muhammad. / De novo myocardial regeneration : Advances and pitfalls. In: Antioxidants and Redox Signaling. 2010 ; Vol. 13, No. 12. pp. 1867-1877.
@article{cbea4099a5204b7bbd864840085d3c20,
title = "De novo myocardial regeneration: Advances and pitfalls",
abstract = "The capability of adult tissue-derived stem cells for cardiogenesis has been extensively studied in experimental animals and clinical studies for treatment of postischemic cardiomyopathy. The less-than-anticipated improvement in the heart function in most clinical studies with skeletal myoblasts and bone marrow cells has warranted a search for alternative sources of stem cells. Despite their multilineage differentiation potential, ethical issues, teratogenicity, and tissue rejection are main obstacles in developing clinically feasible methods for embryonic stem cell transplantation into patients. A decade-long research on embryonic stem cells has paved the way for discovery of alternative approaches for generating pluripotent stem cells. Genetic manipulation of somatic cells for pluripotency genes reprograms the cells to pluripotent status. Efforts are currently focused to make reprogramming protocols safer for clinical applications of the reprogrammed cells. We summarize the advancements and complicating features of stem cell therapy and discuss the decade-and-a-half-long efforts made by stem cell researchers for moving the field from bench to the bedside as an adjunct therapy or as an alternative to the contemporary therapeutic modalities for routine clinical application. The review also provides a special focus on the advancements made in the field of somatic cell reprogramming.",
author = "Haider, {Khawaja Husnain} and Stephanie Buccini and Ahmed, {Rafeeq P.H.} and Muhammad Ashraf",
year = "2010",
month = "12",
day = "15",
doi = "10.1089/ars.2010.3388",
language = "English (US)",
volume = "13",
pages = "1867--1877",
journal = "Antioxidants and Redox Signaling",
issn = "1523-0864",
publisher = "Mary Ann Liebert Inc.",
number = "12",

}

TY - JOUR

T1 - De novo myocardial regeneration

T2 - Advances and pitfalls

AU - Haider, Khawaja Husnain

AU - Buccini, Stephanie

AU - Ahmed, Rafeeq P.H.

AU - Ashraf, Muhammad

PY - 2010/12/15

Y1 - 2010/12/15

N2 - The capability of adult tissue-derived stem cells for cardiogenesis has been extensively studied in experimental animals and clinical studies for treatment of postischemic cardiomyopathy. The less-than-anticipated improvement in the heart function in most clinical studies with skeletal myoblasts and bone marrow cells has warranted a search for alternative sources of stem cells. Despite their multilineage differentiation potential, ethical issues, teratogenicity, and tissue rejection are main obstacles in developing clinically feasible methods for embryonic stem cell transplantation into patients. A decade-long research on embryonic stem cells has paved the way for discovery of alternative approaches for generating pluripotent stem cells. Genetic manipulation of somatic cells for pluripotency genes reprograms the cells to pluripotent status. Efforts are currently focused to make reprogramming protocols safer for clinical applications of the reprogrammed cells. We summarize the advancements and complicating features of stem cell therapy and discuss the decade-and-a-half-long efforts made by stem cell researchers for moving the field from bench to the bedside as an adjunct therapy or as an alternative to the contemporary therapeutic modalities for routine clinical application. The review also provides a special focus on the advancements made in the field of somatic cell reprogramming.

AB - The capability of adult tissue-derived stem cells for cardiogenesis has been extensively studied in experimental animals and clinical studies for treatment of postischemic cardiomyopathy. The less-than-anticipated improvement in the heart function in most clinical studies with skeletal myoblasts and bone marrow cells has warranted a search for alternative sources of stem cells. Despite their multilineage differentiation potential, ethical issues, teratogenicity, and tissue rejection are main obstacles in developing clinically feasible methods for embryonic stem cell transplantation into patients. A decade-long research on embryonic stem cells has paved the way for discovery of alternative approaches for generating pluripotent stem cells. Genetic manipulation of somatic cells for pluripotency genes reprograms the cells to pluripotent status. Efforts are currently focused to make reprogramming protocols safer for clinical applications of the reprogrammed cells. We summarize the advancements and complicating features of stem cell therapy and discuss the decade-and-a-half-long efforts made by stem cell researchers for moving the field from bench to the bedside as an adjunct therapy or as an alternative to the contemporary therapeutic modalities for routine clinical application. The review also provides a special focus on the advancements made in the field of somatic cell reprogramming.

UR - http://www.scopus.com/inward/record.url?scp=78149332383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149332383&partnerID=8YFLogxK

U2 - 10.1089/ars.2010.3388

DO - 10.1089/ars.2010.3388

M3 - Review article

C2 - 20695792

AN - SCOPUS:78149332383

VL - 13

SP - 1867

EP - 1877

JO - Antioxidants and Redox Signaling

JF - Antioxidants and Redox Signaling

SN - 1523-0864

IS - 12

ER -